PSA Test: What It Actually Measures and Why Women on Testosterone Need to Know

What PSA Actually Is (and Why Women Have It Too)

PSA is a serine protease enzyme encoded by the KLK3 gene, best known for being secreted by prostate epithelial cells in men. The confusion for many women is the word "prostate" in the name. You do not have a prostate, so why would your clinician ever order this test?

The answer lies in Skene's glands, two small glands at the lower end of the urethra that are considered the female homolog of the male prostate. These glands express KLK3 and secrete measurable, though very low, quantities of PSA into the bloodstream. Research published in the British Journal of Urology International confirmed that PSA is detectable in the serum of healthy women and originates partly from Skene's gland tissue.

Because PSA is androgen-dependent, any condition or medication that raises circulating androgens will raise PSA in women. That makes this lab directly relevant to:

• Women on prescribed testosterone therapy (low-dose patches, gels, pellets, or injections)
• Women with polycystic ovary syndrome (PCOS), which is characterized by hyperandrogenism
• Post-menopausal women whose estrogen-to-androgen ratio has shifted
• Women being evaluated for unexplained urological symptoms

PSA is not a "men's test that got ordered by mistake." For women on testosterone, it is a safety monitoring tool.

How the PSA Molecule Works

PSA circulates in two forms: free PSA and PSA bound to alpha-1-antichymotrypsin. Total PSA is the sum of both. In clinical monitoring for women on testosterone, total PSA is what most guidelines track. The free-to-total PSA ratio, used in men to refine prostate cancer risk, has not been validated for routine use in women and should not be over-interpreted if your panel includes it.

What Stimulates PSA Production in Women

Three main drivers increase PSA in women:

1. Androgen exposure. Testosterone and dihydrotestosterone (DHT) bind androgen receptors on Skene's gland epithelium, upregulating KLK3 gene expression. Exogenous testosterone does this predictably and dose-dependently.
2. Estrogen modulation. Estrogen downregulates PSA production in breast tissue (a separate context) but has a more complex interaction in Skene's tissue. Post-menopausal estrogen loss may slightly unmask androgen-driven PSA production.
3. Local inflammation or infection. Skene's gland inflammation, urinary tract infections, and pelvic floor disorders can transiently raise PSA, just as prostatitis raises PSA in men. A single elevated result in a woman deserves clinical context, not immediate alarm.

Normal PSA Ranges in Women

Most healthy pre-menopausal women who are not taking testosterone have a PSA below 0.1 ng/mL, and many standard assays return an undetectable result. The clinical threshold most often cited for women is <0.5 ng/mL, though this is a research-derived figure rather than a guideline-mandated cutoff.

Post-menopausal women tend to run slightly higher baseline PSA values than pre-menopausal women, likely because the relative androgen excess of menopause permits more KLK3 expression. Exact normative ranges for women across life stages remain poorly defined, which is a genuine evidence gap you deserve to know about.

PSA Reference Ranges by Life Stage

| Life Stage | Approximate Typical PSA | Notes | |---|---|---| | Reproductive years (no testosterone) | <0.1 ng/mL | Often undetectable | | PCOS, untreated hyperandrogenism | 0.1-0.3 ng/mL | Androgen-driven elevation | | Perimenopause (no testosterone) | <0.2 ng/mL | Limited normative data | | Post-menopause (no testosterone) | <0.5 ng/mL | Slightly higher than premenopausal | | Women on testosterone therapy | Variable; monitor trend | Baseline then every 6-12 months |

These ranges are extrapolated from small observational studies, not large prospective trials in women. Your individual trend over time matters more than any single number.

PCOS and PSA: A Specific Connection

Women with PCOS have elevated androgens as a core feature of the syndrome. A 2004 study in Fertility and Sterility found that women with PCOS had measurably higher serum PSA than age-matched controls without PCOS, with values correlating with free testosterone levels. This is a clinically useful signal: if your PSA rises on testosterone therapy and you also have PCOS, the combination of endogenous and exogenous androgen exposure may produce a larger PSA response than either alone.

PSA Monitoring During Testosterone Therapy in Women

The 2019 Endocrine Society Clinical Practice Guideline on testosterone therapy in women recommends obtaining a baseline PSA before starting therapy and rechecking at follow-up intervals. The guideline acknowledges that no PSA threshold has been validated as a stopping criterion specifically for women, but an unexplained persistent elevation should prompt further urological or oncological evaluation.

A practical monitoring framework based on current guideline language and the pharmacology of testosterone:

• Before starting testosterone: Obtain baseline total PSA. Document it.
• At 3-6 months: Recheck PSA alongside total testosterone, free testosterone, hematocrit, and lipids.
• Ongoing: Annually if values are stable. More frequently if PSA is rising or dose is being titrated upward.
• If PSA rises >0.5 ng/mL above baseline: Pause and investigate before continuing. Rule out UTI, Skene's gland inflammation, and any urological pathology.

This framework is specific to women and differs from PSA monitoring in transgender men (assigned female at birth, on gender-affirming testosterone), where separate considerations and emerging data apply.

Testosterone Formulations and PSA Response

Not all testosterone formulations produce the same PSA curve in women. Pellets, which release testosterone continuously at higher steady-state levels, tend to produce larger PSA elevations than low-dose transdermal gels or patches. Subcutaneous injections sit in between, depending on dose and frequency.

A 2023 review in the Journal of Clinical Endocrinology and Metabolism noted that women using supraphysiologic testosterone doses, defined as serum testosterone consistently above the upper limit of the female reference range, showed disproportionate PSA rises compared to women maintained within physiologic range. This is one argument for keeping testosterone doses in the range that restores levels to the upper quarter of the normal female range rather than exceeding it.

What a Rising PSA Means in a Woman on Testosterone

A rising PSA in a woman on testosterone most often reflects androgen stimulation of Skene's gland tissue. It does not indicate prostate cancer, because you do not have a prostate. However, a very small number of case reports describe PSA-secreting Skene's gland adenocarcinoma, an extremely rare malignancy that warrants specialist evaluation if PSA rises without an androgen-related explanation.

The differential for a rising PSA in a woman includes:

• Dose increase in testosterone therapy
• Transition from physiologic to supraphysiologic androgen levels
• Concurrent PCOS-related androgen excess
• Skene's gland infection or inflammation
• Rare Skene's gland pathology

A single elevated result is not an emergency. A consistently rising trend, particularly one that does not correlate with a dose change, deserves a urology or gynecologic-oncology referral.

PSA and Female-Relevant Conditions

HSDD and Testosterone Therapy

Hypoactive sexual desire disorder (HSDD) is one of the most common reasons clinicians prescribe off-label testosterone to women in the United States. The ISSWSH position statement on testosterone use for HSDD acknowledges that while testosterone improves sexual desire in post-menopausal women, monitoring parameters including PSA should be in place. PSA is listed as part of the safety surveillance panel precisely because androgen-sensitive tissues in women respond to testosterone therapy.

Post-Menopausal Women

Post-menopausal women represent the group most studied for testosterone therapy in women, and their PSA response is the best characterized. A randomized trial by Davis et al. Published in The Lancet showed that a 300 mcg/day testosterone patch significantly improved sexual function in surgically menopausal women. PSA was monitored throughout and rose modestly but remained within normal female ranges in most participants, a reassurance for post-menopausal women starting therapy.

Perimenopause

In perimenopause, circulating androgens are actually declining alongside estrogen, though they fall more slowly. Women in perimenopause who start testosterone for symptoms like low libido, fatigue, or cognitive fog may see a PSA rise from a very low baseline. Because perimenopausal normative PSA data in women on testosterone are thin, monitoring trend rather than absolute value is especially important in this group.

PCOS in Reproductive Years

Women with PCOS who are prescribed low-dose testosterone (occasionally for HSDD or other indications) enter therapy with a higher baseline androgen burden. Their PSA may respond more briskly to testosterone than a woman without PCOS. This is not a contraindication to therapy, but clinicians should document a pre-treatment baseline and track it carefully.

Evidence Gaps: What We Do Not Know Yet

Women have been consistently underrepresented in studies of testosterone pharmacology, and PSA normative ranges for women across the lifespan are a direct casualty of that gap. Here is what is extrapolated versus directly studied:

| Claim | Evidence Status | |---|---| | PSA rises with exogenous testosterone in women | Directly studied; consistent across small trials | | Normal PSA range for women on testosterone | Extrapolated from male data and small observational studies | | PSA threshold that should stop testosterone therapy in women | Not established; expert opinion only | | PSA as a cancer screening tool in women | Not validated; Skene's gland carcinoma is too rare for screening | | PSA differences by testosterone formulation in women | Limited; pellet data especially sparse |

When your clinician says "your PSA looks fine," ask them what reference range they are using and whether it is female-specific. Many labs still flag female PSA results against male reference ranges, which is clinically meaningless.

How to Lower PSA in Women

If your PSA is rising on testosterone therapy, the most direct intervention is dose reduction. The Endocrine Society guideline recommends titrating testosterone to the lowest effective dose that relieves symptoms, which also limits PSA stimulation.

Other steps that may reduce PSA in women:

• Switching formulation. Moving from pellets to a lower-dose transdermal gel may reduce peak androgen exposure and flatten the PSA curve.
• Treating concurrent hyperandrogenism. In women with PCOS, managing insulin resistance and androgen excess with metformin or inositol may modestly lower circulating androgens and secondary PSA.
• Addressing Skene's gland inflammation. If a UTI or local infection is contributing, treating the infection will allow PSA to return to the androgen-driven baseline.
• Lifestyle factors. In men, aerobic exercise, anti-inflammatory diet, and weight management are associated with lower PSA. Direct evidence in women is absent, but the androgen-lowering effects of weight loss in PCOS are well-documented and would logically reduce androgen-driven PSA stimulation.

There is no supplement or medication with proven PSA-lowering efficacy specifically studied in women. 5-alpha-reductase inhibitors (finasteride, dutasteride) lower PSA dramatically in men by blocking DHT conversion, but they are teratogenic and contraindicated in women who could become pregnant, limiting their use almost entirely to post-menopausal women in a handful of dermatological contexts.

Pregnancy, Lactation, and Contraception Considerations

Testosterone therapy is contraindicated in pregnancy. Exogenous androgens cause virilization of a female fetus and are associated with fetal harm. If you are on testosterone therapy for any reason and there is any chance you could become pregnant, reliable contraception is required throughout treatment. This is not a theoretical concern: testosterone does not reliably suppress ovulation, and unintended pregnancies have occurred in women on low-dose testosterone for HSDD.

PSA monitoring is not relevant during pregnancy because testosterone therapy must be stopped before or immediately upon confirmation of pregnancy. After stopping, PSA returns toward baseline within weeks as androgen stimulation of Skene's tissue diminishes.

Lactation: testosterone is expressed in breast milk. The effect on nursing infants is not established. Women on testosterone who wish to breastfeed should discuss the risk-benefit balance with their prescribing clinician. Most guideline authors recommend against concurrent testosterone therapy and breastfeeding given the androgen exposure risk to the infant.

If you are trying to conceive, testosterone therapy should be paused. Testosterone does not improve fertility and may suppress it by disrupting the hypothalamic-pituitary-ovarian axis. PSA monitoring is irrelevant during a conception attempt for the same reason: the drug causing the PSA elevation is discontinued.

Who Should Have PSA Monitored and Who Does Not Need It

PSA monitoring is appropriate for women who:

• Are taking prescribed testosterone therapy in any formulation
• Have a known diagnosis of PCOS with significant hyperandrogenism and are starting an androgen-related treatment
• Have unexplained urological symptoms and a Skene's gland pathology is being evaluated
• Are transgender men on gender-affirming testosterone (different protocols apply, but PSA is still relevant)

PSA monitoring is generally not indicated for women who:

• Are not taking exogenous androgens and do not have PCOS or other hyperandrogenic conditions
• Are on hormone therapy with estrogen only or estrogen-plus-progestogen (no testosterone component)
• Are seeking prostate cancer screening, which is not applicable because women do not have a prostate

The USPSTF prostate cancer screening recommendation applies to men only and has no clinical translation to women. If a lab panel you received includes PSA and you were not expecting it, ask your clinician why it was ordered. It may have been added as part of a testosterone monitoring panel, a PCOS workup, or it may have been ordered in error.

Interpreting Your PSA Result: A Practical Guide for Women

When you get your results, look for these things:

1. The number itself. Is it under 0.1 ng/mL (typical for women not on testosterone), between 0.1 and 0.5 ng/mL (low-level, likely androgen-driven), or above 0.5 ng/mL (needs clinical context)?

2. The trend. A PSA of 0.3 ng/mL that was 0.1 ng/mL six months ago is more informative than a single 0.3 ng/mL result. A doubling or tripling in six months warrants investigation even if the absolute number remains low.

3. The reference range on your lab report. Many commercial labs print a male reference range (typically <4.0 ng/mL) on results from women. This range is not appropriate for you. A PSA of 0.8 ng/mL would look "normal" against a male cutoff of 4.0 ng/mL but is actually elevated for a woman and should prompt a conversation.

4. Concurrent labs. Your PSA result makes the most sense alongside your total testosterone, free testosterone, and SHBG on the same blood draw. If your testosterone is in the upper physiologic range and your PSA is 0.2 ng/mL, that is a coherent picture. If your testosterone is low-normal and your PSA is 0.8 ng/mL, the discordance is worth explaining.

"PSA in women is an underutilized but genuinely informative marker when testosterone therapy is part of the clinical picture," state the authors of the 2019 Endocrine Society guideline on testosterone therapy in women, who specifically call out PSA as part of the recommended monitoring panel. That recommendation exists precisely because the field has recognized that PSA is not male-exclusive physiology.